From: The genetic landscape and possible therapeutics of neurofibromatosis type 2
NIH criteriaa | Manchester criteriaa | 2016 consensusa | 2019 consensusa | 2022 consensusa |
---|---|---|---|---|
1. Bilateral 8th nerve massesb | 1. Bilateral VS | 1. Bilateral VS aged < 70 years | 1. Same as 2016 | 1. Bilateral VS |
2. FDR with NF2, plus - unilateral 8th nerve mass, or -two NF-related lesionsc | 2. FDR with NF2, plus - unilateral VS, or -two NF-related lesionsc | 2. FDR with NF2, plus unilateral VS aged < 70 years | 2. FDR other than siblings with NF2, plus unilateral VS aged < 70 years | 2. Identical NF2 pathogenic variant in ≥ two distinct NF2-related tumorsg, h |
3. Unilateral VS, plus -two NF-related lesionsc | 3. FDR with NF2, or unilateral VS, plus two NF-related lesionsd, e | 3. FDR other than siblings with NF2, or unilateral VS, plus two NF-related lesionsf, e | 3. Two major or one major and two minor criteria, as follows: | |
4. Multiple meningioma, plus -unilateral VS, or -two NF-related lesionsc | 4. Multiple meningioma, plus two of unilateral VS or other NF-related lesionsd | 4. Multiple meningioma, plus two of unilateral VS or other NF-related lesionsf, e | Major criteria: -Unilateral VS -FDR other than siblings with NF2 - ≥ 2 meningiomas - NF2 pathogenic variant in an unaffected tissue (e.g., blood, saliva) | |
5. Constitutional pathogenic NF2 gene variant in blood or identical mutations in two distinct tumors | 5. Same as 2016 | Minor criteria: - > one NF-related lesion - Juvenile subcapsular or cortical cataract, retinal hamartoma, epiretinal membrane in a person aged < 40 years -Specific pattern of genetic changesi |